BRIEF-Myriad Genetics launches the endopredict test in U.S for patients with breast cancer

* Myriad Genetics launches the endopredict test in the United States for patients with breast cancer Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.